An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
about
Anaplastic lymphoma kinase: signalling in development and diseaseEvaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitorsTargeting the hepatocyte growth factor-cMET axis in cancer therapyThe MET axis as a therapeutic target.Clinical use of crizotinib for the treatment of non-small cell lung cancerALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceClinical significance of MET in gastric cancerThe Evolution of Therapies in Non-Small Cell Lung CancerALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsMET inhibitors in combination with other therapies in non-small cell lung cancerALK and ROS1 as a joint target for the treatment of lung cancer: a reviewEmerging importance of ALK in neuroblastomaNon-coding RNAs in lung cancerMet receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancerc-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutationsStereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategyEML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsDetection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingSecond- and third-generation ALK inhibitors for non-small cell lung cancerTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKFAM150A and FAM150B are activating ligands for anaplastic lymphoma kinaseInhibitors of the anaplastic lymphoma kinaseMolecular pathogenesis of peripheral neuroblastic tumorsMET molecular mechanisms and therapies in lung cancerSustained proliferation in cancer: Mechanisms and novel therapeutic targetsFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentStable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK CellsProteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survivalThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityHepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsPolypharmacology in Precision Oncology: Current Applications and Future ProspectsConstitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
P2860
Q24312329-0E25CA18-E56A-4F32-8962-3825D2BE2A1AQ24595585-5EB8C45F-C308-4743-8268-79710888A6FAQ24606259-735E5FF4-6AD6-4EE0-A3CB-92DA5C185A78Q24609682-270740F0-188D-4312-9FEE-AC21D38B9137Q24630466-E2E7C0D2-0E2B-4F6B-8870-EE8FE652CE14Q26775347-B810ADE8-7423-4AA8-B621-2934A6885C79Q26776190-8B71916E-D37E-4234-9E92-DB5648166B56Q26786932-F50E6A52-6D5A-4DBC-81EC-18D2C1236A1FQ26820845-D080F039-ECD8-49BC-ADA6-AAB9936A0835Q26823203-8E0DD3E9-959D-4F4C-8B17-03E8DD619A20Q26851392-A76E42D0-8D02-48C8-A20B-670FCD34864DQ26858819-2CE648AB-160A-48AA-A300-28CF9CCFB179Q26866521-42C7F730-95B9-42E1-9AA5-7DEB5E95F085Q27334957-E76ECFC1-9C74-4D39-B66E-21F75ECA0EF6Q27649203-1878130E-A28F-4E3A-8752-DE06AF980DB9Q27682798-B83BF827-478F-4218-A4C9-34164CA76704Q27851440-95879ADE-EC0A-4649-B1C4-6E96185BDD05Q27851681-6C826C05-DF56-4BED-9200-234F6E6D42B5Q27853138-B45ABB7F-9B44-47CE-89F5-BD1670CAADA1Q27853157-810AC707-8558-49FF-B9E7-21A3828320B7Q27853167-5E012E60-5811-4073-AEC1-EDA4ADD65327Q28072496-4F3B8161-A971-4681-A184-CDF3FD881FCFQ28083446-8E663018-E13C-44D4-A2A6-FF75642256CCQ28118071-C99EA228-BD2B-452D-BA24-065409813A11Q28267124-70C3345D-CBFE-42C2-8345-DE72881EDDCAQ28271405-1F2A10B4-15FB-41BB-9F52-11CA2AE82439Q28272688-9E9AF99C-C68A-4783-A64A-6A795D9E850FQ28396388-A3C1007A-F6B8-4F8B-975F-A3A9DE79F610Q28533949-7A52A317-45E0-45E0-8026-092958264746Q28553147-E68500E3-0D67-4CAF-9846-E3931E569505Q28833673-2E839E5B-13EF-4202-AAFD-28404E8A2F67Q29547693-869AF813-2091-40AD-BC7E-EE072C6B8643Q30414265-C61D519D-4D3B-4AF1-B4AD-87CB55B07E41Q30422676-1DE29A83-8E82-4D5E-841A-3D965D0C77EAQ30494514-30EDF316-70F1-4CA8-A65C-D52F6962026AQ30502341-27ADC55B-ECAB-4F25-9292-A6E3D46D702BQ30846907-90CBC664-AC5D-449B-BDE4-1097E2AED967Q31062741-1FCCC39C-C4B5-4BE9-8ABA-6B5B173A5550Q33588267-38F7915B-D175-4491-AD07-0F02A510F5C7Q33607965-4E116F59-2CDF-49EB-966C-628D08A78286
P2860
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
An orally available small-mole ...... and antiangiogenic mechanisms.
@ast
An orally available small-mole ...... and antiangiogenic mechanisms.
@en
An orally available small-mole ...... and antiangiogenic mechanisms.
@nl
type
label
An orally available small-mole ...... and antiangiogenic mechanisms.
@ast
An orally available small-mole ...... and antiangiogenic mechanisms.
@en
An orally available small-mole ...... and antiangiogenic mechanisms.
@nl
prefLabel
An orally available small-mole ...... and antiangiogenic mechanisms.
@ast
An orally available small-mole ...... and antiangiogenic mechanisms.
@en
An orally available small-mole ...... and antiangiogenic mechanisms.
@nl
P2093
P1433
P1476
An orally available small-mole ...... and antiangiogenic mechanisms.
@en
P2093
Barbara Mroczkowski
Gerrit Los
Gordon Alton
Helen Y Zou
James G Christensen
Jingrong J Cui
Joseph H Lee
Maria E Arango
Mitchell D Nambu
Pei-Pei Kung
P304
P356
10.1158/0008-5472.CAN-06-4443
P407
P577
2007-05-01T00:00:00Z